- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 5/02 - Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
Patent holdings for IPC class A61P 5/02
Total number of patents in this class: 77
10-year publication summary
|
4
|
1
|
5
|
3
|
9
|
10
|
8
|
4
|
5
|
1
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Glytech, Inc. | 65 |
8 |
| Novartis AG | 10829 |
3 |
| Sandoz AG | 1418 |
2 |
| Abbvie Inc. | 1800 |
2 |
| Alchemia Limited | 3 |
2 |
| Antisense Therapeutics Ltd. | 29 |
2 |
| Camurus AB | 142 |
2 |
| Shijiazhuang Yiling Pharmaceutical Co., Ltd. | 109 |
2 |
| Nxera Pharma UK Limited | 170 |
2 |
| The General Hospital Corporation | 4735 |
1 |
| The Trustees of the University of Pennsylvania | 4329 |
1 |
| American University | 60 |
1 |
| Beijing SL Pharmaceutical Co.,Ltd. | 2 |
1 |
| The Board of Regents of the University of Oklahoma | 614 |
1 |
| Cedus, Inc. | 1 |
1 |
| Chong Kun Dang Pharmaceutical Corp. | 233 |
1 |
| Entera Bio Ltd. | 47 |
1 |
| Garvan Institute of Medical Research | 67 |
1 |
| Heptares Therapeutics Limited | 76 |
1 |
| Hercules Incorporated | 139 |
1 |
| Other owners | 41 |